pl-2200

PL-2200 is a **novel immediate-release oral formulation of aspirin**, composed of **325 mg acetylsalicylic acid (aspirin) and a lipid suspension of soybean-derived lecithin**[1][3]. The product is designed to deliver the established pharmacological effects of aspirin—analgesic, antipyretic, anti-inflammatory, and antiplatelet—in a formulation developed to potentially reduce upper gastrointestinal injury relative to conventional aspirin tablets. The inclusion of phosphatidylcholine (from lecithin) is intended to form a protective neutral lipid matrix around the aspirin, possibly mitigating some gastric side effects[3]. Mechanistically, PL-2200 acts as a **cyclooxygenase inhibitor**, suppressing prostaglandin synthesis and platelet aggregation via irreversible inhibition of cyclooxygenase-1 (COX-1)[1][2][5]. Developed by PLx Pharma, PL-2200 was submitted via a 505(b)(2) NDA referencing monograph aspirin, targeting indications such as temporary relief of minor aches and pains and antiplatelet activity[7].

Brand names

PL-2200PL2200PL 2200

Other names

PL-2200PL2200PL 2200